Masimo wins $634 million verdict against Apple in high-stakes patent fight over Apple Watch

A federal jury has awarded Masimo Corp. $634 million in a patent infringement lawsuit against Apple Inc., finding that Apple Watch models sold between 2020 and 2022 infringed on Masimo's pulse-oximetry technology patents and legally qualified as "patient monitors." This substantial verdict, one of the largest patent awards in the Central District of California for consumer technology, represents a significant financial outcome for Masimo in a yearslong dispute, though Apple has announced its intention to appeal the decision. The ruling highlights the increasing legal scrutiny and potential liabilities for tech companies integrating medical-grade functionalities into consumer wearables.

Analysis

A federal jury awarded Masimo Corp. $634 million against Apple Inc. for infringing on Masimo's pulse-oximetry patent in Apple Watch models sold between 2020 and 2022. This substantial verdict, representing one of the largest patent awards in the Central District of California for consumer technology, found that the Apple Watch legally qualifies as a "patient monitor." The award aligns with Masimo's requested royalty range, significantly exceeding Apple's proposed damages of $3 million to $6 million.

The core of the dispute centered on the definition of a "patient monitor," with jurors siding with Masimo's interpretation despite Apple's arguments that its device's functionality differed from clinical monitors. Apple has stated its intention to appeal the decision, asserting disagreement with the verdict and claiming the infringed patent expired in 2022, relating to "historic patient monitoring technology."

This ruling follows a history of legal challenges between the two companies, including a 2023 trade-secrets lawsuit mistrial and an earlier International Trade Commission import ban that prompted Apple to redesign certain watch models. The verdict underscores increasing legal scrutiny and potential liabilities for technology companies integrating medical-grade functionalities into consumer wearables, setting a significant precedent for intellectual property in the health tech sector.

Key Decisions for Investors

• For MASI investors, the $634 million verdict is a significant financial win, validating Masimo's intellectual property and potentially boosting future licensing prospects, though the impending appeal introduces uncertainty regarding the finality and timing of the award.
• For AAPL investors, the verdict represents a material financial liability and a potential operational challenge given the prior ITC import ban, necessitating close monitoring of the appeal process and any required product redesigns or licensing agreements.
• Investors in companies integrating medical-grade technology into consumer devices should assess their intellectual property strategies and potential exposure to similar patent infringement claims, as this case highlights increased legal risks in the health tech convergence space.